Having identified 19 tumor specimens with > 99% test specificity for hyperactive HER and c-Met signaling, we next wanted to determine the potency of the pan-HER inhibitors for HER initiated dysfunctional signaling on these breast cancer specimens. Here, MET is linked to breast cancer.